Literature DB >> 10051466

Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease.

S H Caldwell1, D H Oelsner, J C Iezzoni, E E Hespenheide, E H Battle, C J Driscoll.   

Abstract

We characterized 70 consecutive patients with cryptogenic cirrhosis to assess major risks for liver disease. Each patient was reevaluated for past alcohol exposure, scored by the International Autoimmune Hepatitis (IAH) score and assessed for viral hepatitis risks and risks for nonalcoholic steatohepatitis (NASH). The results were compared with 50 consecutive NASH patients, 39 nonalcoholic patients age 50 and over with cirrhosis from hepatitis C, and 33 consecutive patients with cirrhosis caused by primary biliary cirrhosis (PBC). Among the cryptogenic group, 49 (70%) were female, and the mean age was 63 +/- 11 years. Although ascites and variceal bleeding were common, almost one half lacked major signs of complicated portal hypertension. A history of Type 2 diabetes mellitus and/or obesity was present in 51 (73%). Nineteen (27%) patients had a history of blood transfusions antedating the diagnosis of cirrhosis. No clinical or histological features distinguished this group from the other patients, and 14 (74%) of these had a history of obesity and/or diabetes. Nineteen of the remaining nontransfused patients had indeterminant IAH scores but were histologically and biochemically indistinguishable from the others. Twelve of these (63%) also had a history of obesity and/or diabetes. Both diabetes and obesity were significantly more common in the cryptogenic cirrhotic patients compared with the cirrhotic patients with PBC or hepatitis C. In contrast, the prevalence of obesity and diabetes was similar to the NASH patients who were, on average, a decade younger. Although there is some diversity that indicates more than one cause, our findings suggest that NASH plays an under-recognized role in many patients with cryptogenic cirrhosis, most of whom are older, type 2 diabetic and obese females.

Entities:  

Mesh:

Year:  1999        PMID: 10051466     DOI: 10.1002/hep.510290347

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  234 in total

1.  Nutrition in hepatic failure and liver transplantation.

Authors:  J Aranda-Michel
Journal:  Curr Gastroenterol Rep       Date:  2001-08

2.  Prevalence of transaminase abnormalities in asymptomatic, healthy subjects participating in an executive health-screening program.

Authors:  Cary H Patt; Hwan Y Yoo; Kourosh Dibadj; John Flynn; Paul J Thuluvath
Journal:  Dig Dis Sci       Date:  2003-04       Impact factor: 3.199

3.  Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates.

Authors:  Paola Loria; Amedeo Lonardo; Francesca Leonardi; Cristina Fontana; Lucia Carulli; Anna Maria Verrone; Andrea Borsatti; Marco Bertolotti; Fabio Cassani; Alberto Bagni; Paolo Muratori; Dorval Ganazzi; Francesco B Bianchi; Nicola Carulli
Journal:  Dig Dis Sci       Date:  2003-11       Impact factor: 3.199

4.  Non-alcoholic fatty liver disease: is iron relevant?

Authors:  Julia O'Brien; Lawrie W Powell
Journal:  Hepatol Int       Date:  2011-08-12       Impact factor: 6.047

Review 5.  Cryptogenic cirrhosis: what are we missing?

Authors:  Stephen Caldwell
Journal:  Curr Gastroenterol Rep       Date:  2010-02

Review 6.  Understanding mechanisms of the pathogenesis of nonalcoholic fatty liver disease.

Authors:  Metin Basaranoglu; Serra Kayacetin; Nevin Yilmaz; Ertugrul Kayacetin; Orhan Tarcin; Abdullah Sonsuz
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

7.  Hepatic gene expression of Caucasian and African-American patients with obesity-related non-alcoholic fatty liver disease.

Authors:  Maria Stepanova; Noreen Hossain; Arian Afendy; Kellie Perry; Zachary D Goodman; Ancha Baranova; Zobair Younossi
Journal:  Obes Surg       Date:  2010-01-30       Impact factor: 4.129

8.  Obesity and microvascular invasion in hepatocellular carcinoma.

Authors:  Abby B Siegel; Shuang Wang; Judith S Jacobson; Dawn L Hershman; Emerson A Lim; Jeanette Yu; Lauren Ferrante; Kalpana M Devaraj; Helen Remotti; Shannon Scrudato; Karim Halazun; Jean Emond; Lorna Dove; Robert S Brown; Alfred I Neugut
Journal:  Cancer Invest       Date:  2010-12       Impact factor: 2.176

Review 9.  Hepatic steatosis and type 2 diabetes mellitus.

Authors:  Jeanne M Clark; Anna Mae Diehl
Journal:  Curr Diab Rep       Date:  2002-06       Impact factor: 4.810

Review 10.  Non-alcoholic fatty liver disease: an emerging pathological spectrum.

Authors:  Elie Serge Zafrani
Journal:  Virchows Arch       Date:  2003-12-18       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.